Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 8/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
| ▸ | MMP12 | P39900 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MMP1 | P03956 | 8/20 | 0.43 |
| ▸ | MMP3 | P08254 | 7/20 | 0.43 |
| ▸ | MMP7 | P09237 | 6/20 | 0.43 |
| ▸ | MMP13 | P45452 | 4/20 | 0.43 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656131 | 0.87 | MMP9 (0.61) | MMP9MMP2MMP12MMP1MMP3 | |
| SCHEMBL1656026 | 0.86 | MMP2 (0.52) | MMP9MMP2MMP12PKMHTT | |
| SCHEMBL2927653 | 0.85 | MMP9 (0.68) | MMP9MMP2MMP12MEN1KMT2A | |
| SCHEMBL1658416 | 0.84 | MMP9 (0.67) | MMP9MMP2MMP12MEN1KMT2A | |
| SCHEMBL1655602 | 0.84 | MMP9 (0.67) | MMP9MMP2MMP12MEN1KMT2A | |
| SCHEMBL1656824 | 0.83 | MMP9 (0.65) | MMP9MMP2MMP12MEN1KMT2A | |
| SCHEMBL2927874 | 0.83 | MMP9 (0.65) | MMP9MMP2MMP12MEN1KMT2A | |
| SCHEMBL1656110 | 0.83 | MMP9 (0.65) | MMP9MMP2MMP12MEN1KMT2A | |
| SCHEMBL1655592 | 0.83 | ALDH1A1 (0.49) | MMP9MMP2MMP12KMT2AMMP1 | |
| SCHEMBL1655650 | 0.82 | MMP9 (0.65) | MMP9MMP2MMP12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | claimed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | claimed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| US-7932389-B2 | treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis | MERCK SERONO S.A. (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| EP-1768979-B1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | MERCK SERONO SA (CH) | 2010-09-29 | — | — | EP | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-06-19 | — | — | US | disclosed |
| EP-1768979-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006008303-A1 | OCTAHYDROPYRROLO[2, 3, C]PYRIDINE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146806-A1 | Octahydropyrrolo[2,3C]Pyridine Derivatives and Pharmaceutical Use Thereof | PNPO, NLRP3, CHRM3 | MMP9 1358/4885MMP2 2336/4885MMP12 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.